ATE388237T1 - Dendritische zellhybride - Google Patents

Dendritische zellhybride

Info

Publication number
ATE388237T1
ATE388237T1 AT98918140T AT98918140T ATE388237T1 AT E388237 T1 ATE388237 T1 AT E388237T1 AT 98918140 T AT98918140 T AT 98918140T AT 98918140 T AT98918140 T AT 98918140T AT E388237 T1 ATE388237 T1 AT E388237T1
Authority
AT
Austria
Prior art keywords
dendritic cell
cell hybrids
methods
dendritic
compositions
Prior art date
Application number
AT98918140T
Other languages
English (en)
Inventor
Jianlin Gong
Donald Kufe
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE388237T1 publication Critical patent/ATE388237T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Photovoltaic Devices (AREA)
AT98918140T 1997-04-15 1998-04-15 Dendritische zellhybride ATE388237T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4360997P 1997-04-15 1997-04-15

Publications (1)

Publication Number Publication Date
ATE388237T1 true ATE388237T1 (de) 2008-03-15

Family

ID=21928022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98918140T ATE388237T1 (de) 1997-04-15 1998-04-15 Dendritische zellhybride

Country Status (8)

Country Link
US (1) US6652848B1 (de)
EP (1) EP1007720B1 (de)
JP (2) JP2002501377A (de)
AT (1) ATE388237T1 (de)
AU (1) AU744042B2 (de)
CA (1) CA2286873C (de)
DE (1) DE69839215T2 (de)
WO (1) WO1998046785A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
AU2001238236B2 (en) * 1997-04-15 2007-02-15 Dana-Farber Cancer Institute, Inc. Cytotoxic t lymphocytes activated by dendritic cell hybrids
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
EP1071436A4 (de) * 1998-01-26 2003-08-27 Dana Farber Cancer Inst Inc Hybride immun-effektorzellen
US6389455B1 (en) * 1998-09-22 2002-05-14 Richard C. Fuisz Method and apparatus for bouncing electronic messages
CN1353575A (zh) * 1999-03-31 2002-06-12 匹兹堡大学联邦制高等教育 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞
AU1141901A (en) * 1999-10-22 2001-04-30 Peter Leskovar Cell constructs that are suitable for immunotherapy, the production and the use thereof
KR100363587B1 (ko) * 1999-11-12 2002-12-06 이시우 대식세포와 종양세포의 융합에 의한 항종양 세포성 치료제
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US20090087450A1 (en) 2000-01-11 2009-04-02 Greenville Hospital System Combination therapy of hybrid cells with BCG injection for treating Cancer Patients
US20070212338A1 (en) * 2000-01-11 2007-09-13 Greenville Hospital System Hybrid cells
EP1541675A3 (de) * 2000-01-11 2007-08-08 Greenville Hospital System Aus Antigene presentierenden Zellen erhärtlich Zellhybride
JP2003519486A (ja) 2000-01-11 2003-06-24 グリーンビル ホスピタル システム 雑種細胞
EP1263928B1 (de) * 2000-02-11 2007-09-26 Dana-Farber Cancer Institute, Inc. Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
DE10009030A1 (de) * 2000-02-27 2001-09-20 Univ Eberhard Karls Impfstoff
AU2000236583A1 (en) * 2000-02-27 2001-09-03 Eberhard-Karls-Universitattubingen Universitatsklinikum Hybrid cell vaccines
DE10024384A1 (de) * 2000-05-17 2001-11-29 Mack Gerd R Herstellung von dendritischen Zellen aus Rückenmarkstammzellen
CA2426366A1 (en) * 2000-10-20 2002-04-25 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
DE10139428A1 (de) * 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
JPWO2005083062A1 (ja) * 2004-02-26 2008-01-17 ジェノミディア株式会社 細胞ワクチン
WO2005084387A2 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
US20080031900A1 (en) * 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
CN109385400A (zh) * 2017-08-09 2019-02-26 科济生物医药（上海）有限公司 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
EP4319800A1 (de) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur behandlung von krebs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348878A (en) 1990-05-10 1994-09-20 Dana-Farber Cancer Institute Class I MHC-restricted T-T hybridomas, and a CD8-transfected BW5147, fusion partner therefor
ATE260971T1 (de) 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
WO1993020185A1 (en) 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
IT1264516B1 (it) 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
DE69424299T2 (de) * 1993-10-01 2000-08-31 Minnesota Mining And Mfg. Co., St. Paul Sprachübertragungsadapter für eine atmungsmaske
CA2178950A1 (en) 1993-12-14 1995-06-22 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
JPH10505498A (ja) 1994-09-09 1998-06-02 ザイモジェネティクス，インコーポレイティド 不死化細胞の調製
EP0839044B1 (de) 1995-03-31 2005-05-18 Universite Libre De Bruxelles DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT
JP2001502907A (ja) * 1996-10-25 2001-03-06 ダナ―ファーバー キャンサー インスティテュート インク． ムチンが介在した免疫調節
CN1353575A (zh) 1999-03-31 2002-06-12 匹兹堡大学联邦制高等教育 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞

Also Published As

Publication number Publication date
JP2008263997A (ja) 2008-11-06
DE69839215T2 (de) 2009-03-19
CA2286873C (en) 2010-07-13
EP1007720A1 (de) 2000-06-14
EP1007720A4 (de) 2001-10-24
JP2002501377A (ja) 2002-01-15
EP1007720B1 (de) 2008-03-05
CA2286873A1 (en) 1998-10-22
WO1998046785A1 (en) 1998-10-22
DE69839215D1 (de) 2008-04-17
AU7112098A (en) 1998-11-11
US6652848B1 (en) 2003-11-25
AU744042B2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
DE69839215D1 (de) Dendritische zellhybride
AP2001002225A0 (en) 1-heterocycle substituted diarylamines.
EP0948073A4 (de) Elektrolytische lösung und vorrichtung zur generierung elektrischer energie mit dieser lösung
EP1357403A3 (de) Verfahren zur Erzeugung elektrischer Energie in einem Bohrloch
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
PL331853A1 (en) Derivatives of adenosine n6- substituted with heterocyclic groups
AU1750297A (en) Humanized green fluorescent protein genes and methods
MX9800125A (es) Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
EP2278022A3 (de) Expressionsvektoren, Transfektionssysteme und Verfahren zu deren Verwendung
WO2001090345A3 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
DK0842289T3 (da) Homolog rekombination i eukaryote celler med inaktiveret fejlparringsreparation
NO975557D0 (no) Immortalisering og dismortalisering av celler
DE59603678D1 (de) Kohlenhydratmodifizierte cytostatika
DK1025245T3 (da) Hurtig etablering af stabile pattedyrscelelinjer, der producerer höje koncentrationer af rekombinante proteiner
IT8921243A0 (it) Nuovi geni ibridi funzionali di bacillus thuringiensis ottenuti mediante ricombinazione in vivo.
IT1264516B1 (it) Cellule dendritiche immortalizzate
PT1272633E (pt) Composições e métodos para imunoterapia baseada em células dendríticas
ES8305039A1 (es) "metodo de producir nuevas lineas de celulas t humanas".
BG104291A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
GB2399819A (en) Method of transducing es cells
PT1235579E (pt) Composicoes farmaceuticas contendo trimegestona
GB9919409D0 (en) Baculovirus expression system
DE69619808D1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
ZA9810371B (en) Th2 cell depletion; compositions; methods.
AU1337783A (en) New fibrionoltic enzymes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties